Anixa Biosciences Files 2024 10-K

TL;DR

Anixa Biosciences filed its 2024 10-K, detailing financials and operations. Check R&D and G&A spend.

AI Summary

Anixa Biosciences Inc. filed its 10-K for the fiscal year ending October 31, 2024, reporting on its operations and financial condition. The company, formerly known as ITUS Corp and COPYTELE INC, is based in San Jose, California. The filing details financial data, including research and development expenses and general and administrative expenses for the fiscal years 2023 and 2024.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of Anixa Biosciences' financial performance and operational status for the fiscal year 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a biotechnology company, Anixa Biosciences faces inherent risks related to research and development, clinical trials, regulatory approvals, and market competition.

Key Numbers

• 2024-10-31 — Fiscal Year End (Reporting period for the 10-K)
• 2023-11-01 to 2024-10-31 — Fiscal Year 2024 (Period for financial reporting)
• 2022-11-01 to 2023-10-31 — Fiscal Year 2023 (Prior period for financial comparison)

Key Players & Entities

• Anixa Biosciences Inc. (company) — Filer of the 10-K
• ITUS Corp (company) — Former name of Anixa Biosciences Inc.
• COPYTELE INC (company) — Former name of Anixa Biosciences Inc.
• San Jose, CA (location) — Company headquarters
• 2024-10-31 (date) — Fiscal year end

FAQ

Key Financial Figures

• $0.01 — ge on Which Registered: Common Stock, $0.01 par value ANIX The NASDAQ Stock Mar
• $2.97 — ommon stock on the NASDAQ on such date ($2.97): $ 90,560,860 . On January 10, 2025,

Filing Documents

• form10-k.htm (10-K) — 1048KB
• ex14.htm (EX-14) — 47KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-25-001787.txt ( ) — 5274KB
• anix-20241031.xsd (EX-101.SCH) — 31KB
• anix-20241031_cal.xml (EX-101.CAL) — 49KB
• anix-20241031_def.xml (EX-101.DEF) — 163KB
• anix-20241031_lab.xml (EX-101.LAB) — 352KB
• anix-20241031_pre.xml (EX-101.PRE) — 279KB
• form10-k_htm.xml (XML) — 693KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 9 Item 1B. Unresolved Staff Comments 26 Item 1C. Cybersecurity 26 Item 2.

Properties

Properties 27 Item 3.

Legal Proceedings

Legal Proceedings 27 Item 4. Mine Safety Disclosures 27 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 28 Item 6. [Reserved] 29 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 33 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 3 3 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 3 3 Item 9A.

Controls and Procedures

Controls and Procedures 33 Item 9B. Other Information 34 PART III Item 10. Directors, Executive Officers and Corporate Governance 34 Item 11.

Executive Compensation

Executive Compensation 34 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 34 Item 13. Certain Relationships and Related Transactions, and Director Independence 34 Item 14. Principal Accounting Fees and Services 34 PART IV Item 15. Exhibits, Financial Statement Schedules 35 Item 16. Form 10-K Summary 36 i CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Information included in this Annual Report on Form 10-K (this "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in this Report under "Item 1A. – Risk Factors" below. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Report. CERTAIN TERMS USED IN THIS REPORT References in this Report

Business

Item 1. Business Overview Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology. Our therapeutics programs include (i) the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell ("CAR-T") technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc. ("Certainty"), and (ii) until March 2023, the development of anti-viral drug candidates for the treatment of COVID-19. Our vaccine programs include (i) the development of a vaccine against breast cancer, initially focused on triple negative breast cancer ("TNBC"), the most lethal form of breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute ("Wistar"), the nation's first independent biomedical research institute and a leading NCI designated cancer research center, relating to Wistar's chimeric endocrine receptor targeted therapy technology. We have initially focused on the development of a treatment for ovarian cancer, but we also may pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty's equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common s

View Full Filing

View this 10-K filing on SEC EDGAR